Also trades as: NRXPW (NASDAQ) · $vol 0M
NRXP NASDAQ
NRx Pharmaceuticals, Inc.
1W: -13.2%
1M: +2.0%
3M: +23.5%
YTD: +38.5%
1Y: +21.4%
3Y: -10.6%
5Y: -97.1%
$3.54
-0.09 (-2.48%)
Pre-Market: $3.79 (+0.25, +7.06%)
Weekly Expected Move ±10.9%
$3
$3
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$61.2M
52W Range1.62-5.055
Volume1,033,761
Avg Volume1,186,342
Beta2.19
Dividend—
Analyst Ratings
Company Info
CEOJonathan C. Javitt
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-04
Websitenrxpharma.com
1201 Orange Street
Wilmington, DE 19801
US
Wilmington, DE 19801
US
484 254 6134
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Latest News
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option
NRx Pharmaceuticals announces pricing of public offering of common stock
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Casper Joseph Michae | A-Award | 100,000 | $2.39 | 2026-01-27 |
| Casper Joseph Michae | 100,000 | $2.39 | 2026-01-27 | |
| B Group, Inc. | 0 | — | 2025-08-18 | |
| Javitt Jonathan C | A-Award | 125,000 | $1.73 | 2025-04-09 |
| McBride Dennis | A-Award | 25,000 | $1.73 | 2025-04-09 |